KEGG   DRUG: Vonoprazan, amoxicillin and clarithromycin
Entry
D10775            Mixture   Drug                                   
Name
Vonoprazan, amoxicillin and clarithromycin;
Vonosap (TN);
Voquenza (TN)
Component
Vonoprazan fumarate [DR:D10466], (Amoxicillin hydrate [DR:D00229] | Amoxicillin [DR:D07452]), Clarithromycin [DR:D00276]
Class
Metabolizing enzyme substrate
 DG02919  CYP2B6 substrate
 DG01639  CYP2C19 substrate
 DG01644  CYP2D6 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
  DG01522  CYP3A4 inhibitor
Transporter inhibitor
 DG01622  ABCB1 inhibitor
Remark
Therapeutic category: 6199
ATC code: A02BD14
Product: D10775<JP>
Efficacy
Antibacterial
  Disease
Helicobacter pylori infection [DS:H00320]
Comment
Vonoprazan is metabolized by CYP3A4 with some contribution from CYP2B6, CYP2C19 and CYP2D6.
Clarithromycin is an inhibitor and a substrate of CYP3A4, and it is an inhibitor of P-gp.
Metabolism
Enzyme: CYP3A4 [HSA:1576]; CYP2B6 [HSA:1555], CYP2C19 [HSA:1557], CYP2D6 [HSA:1565]
Interaction
CYP inhibition: CYP3A4 [HSA:1576]
Transporter inhibition: ABCB1 [HSA:5243]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A02 DRUGS FOR ACID RELATED DISORDERS
   A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
    A02BD Combinations for eradication of Helicobacter pylori
     A02BD14 Vonoprazan, amoxicillin and clarithromycin
      D10775  Vonoprazan, amoxicillin and clarithromycin <JP>
USP drug classification [BR:br08302]
 Gastrointestinal Agents
  Gastrointestinal Agents, Other
   Amoxicillin/ Clarithromycin/ Vonoprazan
    D10775  Vonoprazan, amoxicillin and clarithromycin
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  61  Antibiotics
   619  Miscellaneous
    6199  Miscellaneous
     D10775  Vonoprazan, amoxicillin and clarithromycin
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG02919  CYP2B6 substrate
   D10775  Vonoprazan, amoxicillin and clarithromycin
  DG01639  CYP2C19 substrate
   D10775  Vonoprazan, amoxicillin and clarithromycin
  DG01644  CYP2D6 substrate
   D10775  Vonoprazan, amoxicillin and clarithromycin
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10775  Vonoprazan, amoxicillin and clarithromycin
 Metabolizing enzyme inhibitor
  DG02852  CYP3A/CYP3A4 inhibitor
   DG01522  CYP3A4 inhibitor
    D10775  Vonoprazan, amoxicillin and clarithromycin
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D10775  Vonoprazan, amoxicillin and clarithromycin
Antimicrobials [BR:br08307]
 Antibacterials
  Cell wall biosynthesis inhibitor, beta-lactam
   Combination for eradication of H. pylori
    D10775  Vonoprazan, amoxicillin and clarithromycin <JP>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10775
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10775
 Drug transporters
  D10775
Other DBs
PubChem: 313046633
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system